QURE - Uniqure NV logo

Uniqure NV

QURE

uniQure N.V. develops gene therapies for rare diseases, focusing on hemophilia B, Huntington's disease, and epilepsy. Its products include HEMGENIX for hemophilia B and candidates AMT-130, AMT-260, AMT-162, and AMT-191 in clinical trials.

⚕️ Healthcare NASDAQ Listed 2007 $ USD
$1,000 invested 10 years ago →$3,210today

Score Overview

1 Year
Score
Net Growth-26.76%
Net TrendShrank
Net Income Consistency—
Rev Growth15.99%
Rev TrendGrew
Revenue Consistency—
5 Years
Score2.6
Net Growth-176.52%
Net Trend40%
Net Income Consistency—
Rev Growth-96.44%
Rev Trend40%
Revenue Consistency—
10 Years
Score
Net Growth-243.73%
Net Trend30%
Net Income Consistency
Rev Growth-25.60%
Rev Trend40%
Revenue Consistency
All Time
Score—
Net Growth—
Net Trend33%
Net Income Consistency
Rev Growth—
Rev Trend54%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Uniqure NV has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by Net Income Consistency.

Has not reached the top 50 on Net Income Consistency in any year we have ranked.

  • QURE

2020: 97.3% · 2021: 93.2% · free through 2021 · longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 23.11—
1 Year2025-10-22
$ 59.91-61.43%
5 Years2021-10-22
$ 28.46-18.80%
10 Years2016-10-21
$ 7.20220.97%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 18M-$ 252M$ 810M
2025$ 16M-$ 198M$ 622M
2024$ 27M-$ 239M$ 367M
2023$ 15M-$ 308M$ 617M
2022$ 106M-$ 126M$ 352M
2021$ 524M$ 329M$ 556M
2020$ 37M-$ 125M$ 244M
2019$ 7M-$ 124M$ 377M
2018$ 11M-$ 83M$ 234M
2017$ 13M-$ 80M$ 159M
2016$ 25M-$ 73M$ 132M
2015$ 10M-$ 78M$ 222M
2014$ 5M-$ 45M$ 64M
2013$ 4M-$ 37M$ 32M
2012-$ 19M$ 347.82K
2011-$ 22M$ 1M
2010$ 23M
QURE - Uniqure NV logo

Uniqure NV fundamental performance

Between 2020 and 2025, revenue declined from $ 37M to $ 16M and net income went from -$ 125M to -$ 198M. Revenue increased in 2 of those 5 years; net income in 2.

Between 2015 and 2025, revenue grew from $ 10M to $ 16M and net income went from -$ 78M to -$ 198M. Revenue increased in 4 of those 10 years; net income in 3.

Uniqure NV currently holds a 5-year HDB Score of 2.6 out of 10. How the HDB Score is calculated.

Membership

Continue QURE’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies